Champions Oncology Net Income vs. Shares Owned By Institutions
| CSBR Stock | USD 4.55 0.28 6.56% |
Net Loss | First Reported 1995-10-31 | Previous Quarter -109 K | Current Value 1.3 M | Quarterly Volatility 1.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.53 | 0.4138 |
|
|
For Champions Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Champions Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Champions Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Champions Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Champions Oncology over time as well as its relative position and ranking within its peers.
Champions |
Champions Oncology's Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.26) | Revenue Per Share 3.807 | Quarterly Revenue Growth 0.119 | Return On Assets (0.07) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Champions Oncology Shares Owned By Institutions vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Champions Oncology's current stock value. Our valuation model uses many indicators to compare Champions Oncology value to that of its competitors to determine the firm's financial worth. Champions Oncology is number one stock in net income category among its peers. It is rated below average in shares owned by institutions category among its peers . Champions Oncology reported last year Net Loss of (7.28 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Champions Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Champions Shares Owned By Institutions vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Champions Oncology |
| = | (7.28 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Champions Oncology |
| = | 50.64 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Champions Shares Owned By Institutions Comparison
Champions Oncology is currently under evaluation in shares owned by institutions category among its peers.
Champions Oncology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Champions Oncology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Champions Oncology will eventually generate negative long term returns. The profitability progress is the general direction of Champions Oncology's change in net profit over the period of time. It can combine multiple indicators of Champions Oncology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -7.4 M | -7 M | |
| Income Before Tax | -7.3 M | -6.9 M | |
| Net Loss | -7.3 M | -6.9 M | |
| Income Tax Expense | -32 K | -30.4 K | |
| Total Other Income Expense Net | 48 K | 50.4 K | |
| Net Loss | -6.1 M | -6.4 M | |
| Net Loss | -7.3 M | -7.6 M | |
| Non Operating Income Net Other | -12.7 K | -13.3 K | |
| Interest Income | 355.5 K | 316 K | |
| Change To Netincome | 1.7 M | 1.6 M | |
| Net Loss | (0.54) | (0.56) | |
| Income Quality | 0.84 | 1.58 | |
| Net Income Per E B T | 1.00 | 1.41 |
Champions Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Champions Oncology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Champions Oncology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Champions Oncology's important profitability drivers and their relationship over time.
Use Champions Oncology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Champions Oncology Pair Trading
Champions Oncology Pair Trading Analysis
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Champions Oncology position
In addition to having Champions Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Buywrite ETFs Thematic Idea Now
Buywrite ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.